Lynk Pharma Starts China Trial of RA Treatment

Hangzhou Lynk Pharma has started a China Phase II trial of a targeted kinase inhibitor in patients with rheumatoid arthritis. The company believes LNK01001 has best-in-class potential for autoimmune disease indications. The Phase II trial is designed to evaluate the safety and efficacy of LNK01001 in patients with moderate to severe active rheumatoid arthritis who have poor response or intolerance to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Lynk has a US partner for LNK01001 that has not been disclosed. More details.... Share this with colleagues: // //